Completed NA INTERVENTIONAL 1-arm NCT02241187

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

Sponsor: Cold Spring Harbor Laboratory

Interventions Cetuximab DW & DCE-MRI PEGPH20 blood draws

Updated 7 times since 2017 Last updated: Sep 25, 2017 Started: Sep 12, 2014 Primary completion: Sep 13, 2016 Completion: Sep 13, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Pancreatic Cancer, this trial is completed. The trial is conducted by Cold Spring Harbor Laboratory and has accumulated 7 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Oct 2017 — Jun 2018 [monthly]

Completed NA

▶ Show 2 earlier versions

Feb 2017 — Oct 2017 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cold Spring Harbor Laboratory
Memorial Sloan Kettering Cancer Center
Weizmann Institute of Science

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States